Regeneron and Partner Announced Positive First Trial Results of Odyssey
Regeneron and its partner Sanofi announced positive results in the first trial of their extensive Phase III ODYSSEY program (12 trials in total) for alirocumab (REGN-727), which targets PCSK9 to lower LDL (or “bad”) cholesterol. Alirocumab showed a 47.2% reduction in LDL levels from baseline over 24 weeks in patients with primary hypercholesterolemia and moderate cardiovascular risk, compared to 15.6% in patients treated with Zetia … Continue reading Regeneron and Partner Announced Positive First Trial Results of Odyssey